Last reviewed · How we verify
CLN-619
At a glance
| Generic name | CLN-619 |
|---|---|
| Sponsor | Cullinan Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (PHASE1)
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CLN-619 CI brief — competitive landscape report
- CLN-619 updates RSS · CI watch RSS
- Cullinan Therapeutics Inc. portfolio CI